- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04827108
Psychometric Properties of the Chinese Version of PeNAT
March 22, 2022 updated by: Dr Katherine Lam, The Hong Kong Polytechnic University
Psychometric Properties of the Chinese Version of the Pediatric Nausea Assessment Tool (PeNAT) to Measure Nausea and Vomiting in Hong Kong Chinese Children Undergoing Chemotherapy
Cancer is a leading cause of death for children.
Chemotherapy is the most common treatment for cancer.
Notwithstanding the improved survival, children with cancer still have to face a significant amount of symptoms associated with chemotherapy.
Two major symptoms induced by chemotherapy are nausea and vomiting.
These two symptoms were demonstrated to cause serious disruption in patients' daily function and quality of life.
Given these devastating impacts, intervening children with appropriate methods to alleviate nausea and vomiting during chemotherapy is therefore crucial.
It is imperative for nurses to develop non-pharmacological interventions to reduce nausea and vomiting, with the goal of improving the QoL of children with cancer when undergoing chemotherapy First, however, careful assessment of nausea and vomiting in children with cancer is a necessary step towards designing appropriate interventions.
This study aims to translate and validate an instrument (PeNAT) which can assess nausea and vomiting among Hong Kong Chinese children and adolescents undergoing chemotherapy
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
Currently, the most effective anti-emetics appear to be 5-HT3 inhibitors, followed by NK1 inhibitors and neuroleptic drugs.
Nevertheless, anti-emetics alone are not sufficient to manage these two symptoms.
This poor symptom control could be due to healthcare professionals' perception that nausea and vomiting are solely biological problems, and their heavy reliance on pharmacological treatment for management.
After literature search, we can identify only one validated instrument, the Pediatric Nausea Assessment tool (PeNAT), assessing chemotherapy-induced nausea and vomiting in children.
Yet, this instruments is not available in Chinese.
This study aims to translate and validate an instrument (PeNAT) which can assess nausea and vomiting among Hong Kong Chinese children and adolescents undergoing chemotherapy
Study Type
Observational
Enrollment (Anticipated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Katherine Lam, PhD
- Phone Number: 27666420
- Email: kwkatlam@polyu.edu.hk
Study Contact Backup
- Name: Eva Ho, PhD
- Phone Number: 27666417
- Email: kyanho@polyu.edu.hk
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
This study targets to recruit 150 subjects from the Hong Kong Children's Hospital.
Children who meet the inclusion criteria will be eligible to participate.
Description
Inclusion Criteria:
- Aged 4 - 17
- A confirmed diagnosis of cancer
- Currently undergoing chemotherapy
- Able to speak Cantonese and read Chinese
Exclusion Criteria:
- Cognitive or behavioral problems in medical records
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Chinese version of the Pediatric Nausea Assessment Tool (PeNAT) at baseline
Time Frame: at baseline
|
Children will be required to fill in the Chinese version of the Pediatric Nausea Assessment Tool (PeNAT) at baseline.
The score ranges from 1 to 4. Higher scores represent a more severe nausea.
|
at baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Chinese version of the Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0) at baseline
Time Frame: at baseline
|
Children will be required to fill in the Chinese version of Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0) at baseline.
The score ranges from 0 to 100.
Higher scores represent a better quality of life.
|
at baseline
|
The Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC) at baseline
Time Frame: at baseline
|
Children will be required to fill in the Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC) at baseline.
The score ranges from 0 to 60. Higher scores represent a higher number of depressive symptoms.
|
at baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Katherine Lam, PhD, The Hong Kong Polytechnic University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 1, 2022
Primary Completion (Anticipated)
February 28, 2024
Study Completion (Anticipated)
August 31, 2024
Study Registration Dates
First Submitted
March 30, 2021
First Submitted That Met QC Criteria
March 30, 2021
First Posted (Actual)
April 1, 2021
Study Record Updates
Last Update Posted (Actual)
March 23, 2022
Last Update Submitted That Met QC Criteria
March 22, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PeNAT validation
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
University of Wisconsin, MadisonCompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject | Stage I Colorectal Cancer | Stage IIIA Colorectal Cancer | Stage IIIB Colorectal Cancer | Stage... and other conditionsUnited States
Clinical Trials on PeNAT validation
-
Zurich University of Applied SciencesUniversitat Politècnica de ValénciaCompletedPrevention Harmful Effects
-
Linkoeping UniversityRecruiting
-
University Medical Center GroningenInternational Centre for Diarrhoeal Disease Research, Bangladesh; Uganda Cancer... and other collaboratorsActive, not recruitingCervix Cancer | HPV Infection | Cervical DysplasiaUganda
-
Andrzej Frycz Modrzewski Krakow UniversityKarolinska Institutet; University of RzeszowCompleted
-
Ludwig Boltzmann Institute for Digital Health and...Salzburger LandesklinikenCompleted
-
University Hospital, GhentUniversity Ghent; BytefliesRecruitingProgressive Multiple SclerosisBelgium
-
Nicole LindenblattNot yet recruitingTrauma | Limb Injury | Patient Reported Outcome MeasuresSwitzerland
-
University of California, San FranciscoBristol-Myers Squibb; Azumio Inc.Active, not recruitingDiabetesUnited States
-
Sehat Medical ComplexCompletedAnkle Disorders InjuriesPakistan